RecruitMe Clinical Trial

The Effect of Dispensed Cannabis on Taxane-Induced Peripheral Neuropathy
Cannabinoids for Taxane-Induced Peripheral Neuropathy in Women Undergoing Breast Cancer Treatment
Sponsor:Thompson Family Foundation Initiative at Columbia University TFFI
Enrolling:Female Patients Only
Study Length:8 Weeks
Clinic Visits:5
Age Range:Between 21 and 60 years old
IRB Number:7635
U.S. Government ID:NCT03782402
Contact: Diana Martinez, MD: 646-774-7774 / dm437@cumc.columbia.edu
Additional Study Information:

Paclitaxel is frequently used to treat breast cancer, but it can also cause neuropathy where the nerves of the hands and feet stop working properly. The symptoms of neuropathy can include pain, numbness, and difficulty with everyday activities like walking or typing. Paclitaxel-induced neuropathy is common and there are few treatment options. Our study will test the effect of cannabis (marijuana) capsules on neuropathy caused by paclitaxel (or docetaxel) in breast cancer patients. The capsules are provided by Tilray, a certified medical cannabis producer and the protocol is FDA approved. Our study lasts for 8 weeks, with several visits per month and careful monitoring. Compensation provided for time and travel.

Do You Qualify?
Have you been diagnosed with breast cancer?YesNo
Did you receive Paclitaxel or Docetaxel as part of your treatment?YesNo
Did you develop neuropathy (nerve problems) as a result?YesNo
Submit
Cancel
Investigator
Diana Martinez, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Diana Martinez, MD
Email: dm437@cumc.columbia.edu
Phone: 646-774-7774